افزایش شیوع بیش از حد چاقی (احشایی) و عوامل خطرزای چاقی مرتبط با قلب و عروق به­طور مستقیم با افزایش میزان بیماری­های قلبی- عروقی و دیابت نوع 2 همراه است (64). بافت چربی سفید اندام درون­ریز مهمّی است که پروتئین­های فعّال بیولوژیکی ترشح می­کند، که این مجموعه آدیپوکین­ها نامیده می­شود (65). این عوامل مشتق شده از WAT شامل آدیپونکتین، لپتین، رزیستین، اپلین، ویسفاتین، واسپین، هپکیدین، چمرین، اُمنتین، PAI-1، αTNF-، IL-6 و آنژیوتانسیوژن می­باشند که این عوامل نقش مرکزی در هموستاز بدن از طریق انواع فرآیندهای زیستی و فیزیولوژیکی بازی می­کنند (66). بافت چربی سفید اضافه، با مشکلات سلامتی مرتبط با چاقی همراه است و باعث ایجاد التهابی مزمن می­شود. التهاب با توسعه­ی مقاومت به انسولین و سندرم متابولیک همراه است. از آن­جا­که هم مقاومت انسولین و هم سندروم متابولیک با اختلالات متابولیکی متعدّدی همراه هستند، خطر بیماری­های قلبی- عروقی و دیابت افزایش می­یابد (64). سطوح اکثر آدیپوسیتوکین­های پلاسما با افزایش بافت چربی و حجم سلول­های چرب افزایش می­یابد شکل (2-1) (64).

2-2-2- عملکرد درونریز سلول‌های چربی: آدیپوسایتوکین‌ها 4

2-2-2-1- آدیپونکتین.. 6

2-2-2-2- واسپین.. 6

2-2-2-3- لپتین.. 6

2-2-2-4- ویسفاتین.. 7

2-2-2-5- پروتئین محرک آسیلاتین (ASP) 7

2-2-2-6- آدیپسین (Adipsin) 9

2-2-2-7- چاقی، مقاومت به انسولین و یائسگی.. 11

3-2- پیشینه تحقیق.. 12

منابع.. 16

برخی از منابع

64.       Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. European heart journal. 2008;29(24):2959-71.

65.       Guo Q. Skeletal Muscle C-Jun N-terminal Kinase (JNK) Activity After Acute Resistive Exercise in Elder Adults with Type 2 Diabetes: Metabolic and Clinical Correlates: University of Sydney; 2011.

66.       Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Digestive diseases and sciences. 2009;54(9):1847-56.

67.       Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mikhailidis DP. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Current drug targets. 2010;11(1):122-35.

68.       Kralisch S, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini reviews in medicinal chemistry. 2007;7(1):39-45.

69.       Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis research and therapy. 2006;8(3):R82.

70.       Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, et al. Exercise and type 2 diabetes the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes care. 2010;33(12):2692-6.

71.       Poulos SP, Hausman DB, Hausman GJ. The development and endocrine functions of adipose tissue. Molecular and cellular endocrinology. 2010;323(1):20-34.

72.       Goropashnaya AV, Herron J, Sexton M, Havel PJ, Stanhope KL, Plaetke R, et al. Relationships between plasma adiponectin and body fat distribution, insulin sensitivity, and plasma lipoproteins in Alaskan Yup'ik Eskimos: the Center for Alaska Native Health Research study. Metabolism. 2009;58(1):22-9.

73.       Hong SC, Yoo SW, Cho GJ, Kim T, Hur JY, Park YK, et al. Correlation between estrogens and serum adipocytokines in premenopausal and postmenopausal women. Menopause. 2007;14(5):835-40.

74.       Li HL, Zhang HL, Jian WX, Li Q, Peng WH, Xu YW. Association of vaspin gene polymorphisms with coronary artery disease in Chinese population and function study. Clinica Chimica Acta. 2013;415:233-8.

75.       Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(30):10610-5.

76.       Bouassida A, Chamari K, Zaouali M, Feki Y, Zbidi A, Tabka Z. Review on leptin and adiponectin responses and adaptations to acute and chronic exercise. British journal of sports medicine. 2008.

77.       Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. Journal of the American College of Cardiology. 2008;52(15):1201-10.

78.       Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426-30.

79.       Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Current medicinal chemistry. 2008;15(18):1851-62.

80.       Baldo A, Sniderman AD, St-Luce S, Avramoglu RK, Maslowska M, Hoang B, et al. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. The Journal of clinical investigation. 1993;92(3):1543-7.

81.       Lesavre PH, Hugli TE, Esser AF, Müller-Eberhard HJ. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. The Journal of Immunology. 1979;123(2):529-34.

82.       Schreiber RD, Müller-Eberhard H. Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins. Journal of Experimental Medicine. 1978;148(6):1722-7.

83.       Cianflone K, Maslowska M, Sniderman AD, editors. Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. Seminars in cell & developmental biology; 1999: Elsevier.

84.       Yasruel Z, Cianflone K, Sniderman AD, Rosenbloom M, Walsh M, Rodriguez MA. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids. 1991;26(7):495-9.

85.       Germinario R, Sniderman AD, Manuel S, Lefebvre SP, Baldo A, Cianflone K. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism-Clinical and Experimental. 1993;42(5):574-80.

86.       Tao Y, Cianflone K, Sniderman AD, Colby-Germinario SP, Germinario RJ. Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism. 1997;1344(3):221-9.

87.       Cianflone K. Acylation stimulating protein and the adipocyte. Journal of endocrinology. 1997;155(2):203-6.

88.       Van Harmelen V, Reynisdottir S, Cianflone K, Degerman E, Hoffstedt J, Nilsell K, et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. Journal of Biological Chemistry. 1999;274(26):18243-51.

89.       Saleh J, Summers LK, Cianflone K, Fielding BA, Sniderman AD, Frayn KN. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. Journal of Lipid Research. 1998;39(4):884-91.